Cynomolgus macaque model for pneumonic plague

Microbial Pathogenesis

Volumn 50, Issue 1, 2011, Pages 12-22

  Warren, Richard ^a   Lockman, Hank ^a   Barnewall, Roy ^a   Krile, Robert ^a   Blanco, Oscar Bermeo ^a   Vasconcelos, Daphne ^a   Price, Jessica ^b   House, Robert V ^b   Bolanowksi, Mark A ^b,c   Fellows, Patricia ^b  

^a BATTELLE MEMORIAL INSTITUTE   (United States)

^b A CSC Company   (United States)

^c ChemicaleBiological Medical Systems/Joint Vaccine Acquisition Program   (United States)

Author keywords

Cynomolgus macaque; Disease pathology; Median lethal dose; Pneumonic plague; Yersinia pestis

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTEREMIA; BLOOD PRESSURE; BREATHING RATE; CIRCADIAN RHYTHM; COLONY FORMING UNIT GM; CONTROLLED STUDY; FEMALE; FEVER; HEART RATE; HISTOPATHOLOGY; LUNG DISEASE; MACACA; MALE; NONHUMAN; PATHOGENESIS; PLEURISY; PNEUMONIC PLAGUE; PRIORITY JOURNAL; TELEMETRY; YERSINIA PESTIS;

AEROSOLS; ANIMALS; BACTEREMIA; DISEASE MODELS, ANIMAL; FEMALE; LETHAL DOSE 50; MACACA FASCICULARIS; MALE; PLAGUE; YERSINIA PESTIS;

ANIMALIA; YERSINIA PESTIS;

EID: 78650624797     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2010.10.002     Document Type: Article

References (36)

1. Hinnebusch B.J., Erickson D.L. Yersinia pestis biofilm in the flea vector and its role in the transmission of plague. Curr Top Microbiol Immunol 2009, 322:229-248.
2. Vadyvaloo V., Jarrett C., Sturdevant D., Sebbane F., Hinnebusch B.J. Analysis of Yersinia pestis gene expression in the flea vector. Adv Exp Med Biol 2007, 603:192-200.
3. Daya M., Nakamura Y. Pulmonary disease from biological agents: anthrax, plague, Q fever, and tularemia. Crit Care Clin 2005, 21:747-763. [vii].
4. Cavanaugh D.C., Caidgan F.C., Williams J.E., Marshall J.D. Plague. Internal Medicine in Vietnam 1982, Vol 2. Office of The Surgeon General and Center of Military History, Washington, DC, Chap 8, Sec 1. A.J. Ognibene, O. Barrett (Eds.).
5. Mee C. How a mysterious disease laid low Europe's masses. Smithsonian 1990, 20:66-79.
6. Williams P., Wallace D. Unit 731: Japan's secret biological warfare in World War II 1989, The Free Press, New York, NY.
7. Barry J. Planning a plague?. Newsweek 1993, (1):40-41. Feb.
8. Center for Disease Control, 2010. Emergency Preparedness and response. http://www.bt.cdc.gov/agent/agent/agentlist-category.asp.
9. Cavanaugh D.C., Elisberg B.L., Llewelly C.H., Marshall J.D., Rust J.H., Williams J.E., et al. Plague immunization. V. Indirect evidence for the efficacy of plague vaccine. J Infect Dis 1974, 129:S37-S40.
10. Williamson E.D., Eley S.M., Griffin K.F., Green M., Russell P., Leary S.E.C., et al. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immun Med Micro 1995, 12:223-230.
11. Williamson E.D., Stagg A.J., Eley S.M., Titball R.W. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. Vaccine 1997, 15:1079-1084.
12. Anderson G.W., Heath D.G., Bolt C.R., Welkos S.L., Friedlander A.M. Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice. Am J Trop Med Hyg 1998, 58(6):793-799.
13. Heath D.G., Anderson G.W., Maruo J.M., Welkos S.L., Andrews G.P., Adamovicz J. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 1998, 16(11/112):1131-1137.
14. Williamson E.D., Eley S.M., Stagg A.J., Green M., Russel P., Titball R.W. A single dose sub-unit vaccine protects against pneumonic plague. Vaccine 2001, 19:566-571.
15. Meyer K.F. Effectiveness of live or killed plague vaccines in man. Bull Wld Hlth Org 1970, 42:653-666.
16. Meyer K.F., Cavanaugh D.C., Bartelloni P.J., Marshall J.D. Plague immunization. I. Past and present trends. J Infect Dis 1974, 129(suppl):S13-S18.
17. Marshal J.D., Bartelloni P.J., Cavanaugh D.C., Kadull P.J., Meyer K.F. Plague immunization. II. Relation of adverse clinical reactions to multiple immunization with killed vaccine. J Infect Dis 1974, 129(suppl):S19-S25.
18. Feodorova V.A., Corbel M.J. Prospects for new plague vaccines. Expert Rev Vaccines 2009, 8(12):1721-1738.
19. Morris S.R. Development of a recombinant vaccine against aerosolized plague. Vaccine 2007, 25(16):3115-3117.
20. World Health Organization - Plague. http://www.who.int/mediacentre/factsheets/fs267/en/.
21. Guidance for industry: animal models- essential elements to address efficacy under the animal rule 2009, Center for Drug Evaluation and Research, Food and Drug Administration Department of Health and Human Services, Rockville, MD. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078923.pdf.
22. Ehrenkranz N.J., Meyer K.F. Studies on immunization against plague. VIII. Study of three immunizing preparations in protecting primates against pneumonic plague. J Infect Dis 1955, 96:138-144.
23. Meyers K.F. Pneumonic plague. Bacteriol Rev 1961, 25:249-261.
24. Davis K.J., Fritz D.L., Pitt M.L., Welkos S.L., Worsham P.L., Friedlander A.M. Pathology of experimental pneumonic plague produced by fraction-1-positive and fraction-1-negative Yersinia pestis in African green monkeys (Cercopithecus aethiops). Arch Pathol Lab Med 1996, 120:156-162.
25. Finegold M.J., Petery J.J., Berendt R.F., Adams H.R. Studies on the pathogenesis of plague. Blood coagulation and tissue responses of macaca mulatta following exposure to aerosols of Pasteurella pestis. Am J Pathol 1968, 53:99-114.
26. Van Andel R., Sherwood R., Gennings C., Lyons C.R., Hutt J., Gigliotti A., et al. Clinical and pathologic features of cynomolgus macaques (Macaca fascicularis) infected with aeroslized Yersinia pestis. Comp Med 2008, 58:68-75.
27. Adamovicz J.J., Worsham P.L. Plague. Biodefense Research methodology and animal models 2006, CSC Press, Boca Raton, FL, P. 107-135. J.R. Swearengen (Ed.).
28. Franz D.R., Jahrling P.B., Friedlander A.M., McClain D.J., Hoover D.L., Bryne W.R., et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997, 278:399-411.
29. Meyers K.F., Smith G., Foster L., Brookman M., Sung M. Live, attenuated Yersinia pestis vaccine: virulent in nonhuman primates, harmless to guinea pigs. J Infect Dis 1974, 129(suppl):S85-S112.
30. Cornelius C.A., Quenee L.E., Overheim K.A., Koster F., Brasel T.L., Elli D., et al. Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague. Infect Immun 2008, 76(12):5588-5597.
31. Guarner J., Shieh W.J., Greer P.W., Gabastou J.M., Chu M., Hayes E., et al. Immunohistochemical detection of Yersinia pestis in formalin-fixed, paraffin-embedded tissue. Am J Clin Pathol 2002, 117:205-209.
32. Institute of Laboratory animal Resources. Guide for the Care and use of Laboratory animals 1996, National Research Council, National Academies Press, Washington, DC.
33. Feder P.I., Hobson D.W., Olson C.T., Joiner R.L., Matthews M.C. Statistical design considerations for stagewise, adaptive dose allocation in dose-response studies. Biopharmaceutical Sequential statistical applications 1992, Marcel Dekker, New York. K.E. Peace (Ed.).
34. Feder P.I., Olson C.T., Hobson D.W., Matthews M.C., Joiner R.L. Statistical analysis of dose-response experiments by maximum likelihood analysis and iteratively reweighted nonlinear least squares regression techniques. Drug Inf J 1991, 25:323-334.
35. Fieller E.C. A fundamental formula in the statistics of biological assay, and some applications. Quart J Pharm 1944, 117-123.
36. Finney D. Probit analysis 1971, Cambridge University Press, Cambridge, England.